QIM
SGNT

Quest Investment Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Quest Investment Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-16,570
Closed -$387K – 237
2014
Q1 		$387K Sell
16,570
-635
-4% -$13.9K 0.04% 162
2013
Q4 		$437K Buy
+17,205
New +$389K 0.04% 146

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

Quest Investment Management's SGNT Position: Q2 2014 in Review

Quest Investment Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2014, closing a stake of 16,570 shares — an estimated $387K sold.

Quest Investment Management first reported a position in SGNT in Q4 2013 and held it in 2 quarters. The position peaked at $437K in Q4 2013. 104 funds tracked by Wall St. Rank hold SGNT as of Q2 2014.

  • Quest Investment Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Quest Investment Management sold 16,570 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2014, an estimated $387K.
  • Quest Investment Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2013 and held it in 2 quarters.
  • Quest Investment Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $437K in Q4 2013.
  • 104 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2014.

Based on Quest Investment Management's 13F filing for Q2 2014, filed 11 Aug 2014.